Cohen Investment Advisors LLC Has $2.51 Million Holdings in Pfizer Inc. $PFE

Cohen Investment Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 16.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,490 shares of the biopharmaceutical company’s stock after buying an additional 14,984 shares during the quarter. Cohen Investment Advisors LLC’s holdings in Pfizer were worth $2,509,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PFE. Pacer Advisors Inc. boosted its holdings in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Amundi raised its stake in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Nuveen LLC bought a new stake in Pfizer in the 1st quarter valued at $389,861,000. Goldman Sachs Group Inc. raised its stake in Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after acquiring an additional 9,041,990 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock valued at $254,574,000 after acquiring an additional 7,581,030 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Morgan Stanley increased their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.41.

Pfizer Stock Down 2.3%

Shares of NYSE PFE opened at $25.67 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The stock has a market capitalization of $145.95 billion, a P/E ratio of 13.65, a PEG ratio of 0.86 and a beta of 0.55. The stock’s fifty day moving average is $24.79 and its 200 day moving average is $24.15.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the business earned $0.60 earnings per share. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.